{"product_id":"xerispharma-five-forces-analysis","title":"Xeris Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eXeris faces nuanced competitive pressures—from concentrated suppliers and cost-sensitive buyers to evolving substitute threats and regulatory headwinds—and this snapshot highlights where strategic risk and opportunity meet. Our concise assessment flags key vulnerabilities and competitive levers that matter for valuation and planning. This brief only scratches the surface; unlock the full Porter's Five Forces Analysis for force-by-force ratings, visuals, and actionable guidance tailored to Xeris.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized sterile fill-finish\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReady-to-use injectables depend on scarce high-spec sterile fill-finish capacity, often concentrated among a handful of CMOs, creating bottlenecks and meaningful switching costs for Xeris; in 2024 the FDA drug shortages list still showed over 100 active shortages, many tied to sterile injectables, underscoring supply fragility. This concentration increases CMO pricing power and prioritization risk; dual-sourcing reduces but does not eliminate capacity constraints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical device and component vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutoinjectors, prefilled syringes and delivery components are sourced from a small set of specialized suppliers with specific tooling and combination-product expertise. Tooling, regulatory validation and compatibility create 12–24 month qualification lock-in (2024 industry standard), raising switching costs. Any quality deviation can trigger recalls or supply interruptions, giving qualified vendors leverage to negotiate favorable commercial and lead-time terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary excipients and solvents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeriSol\/XeriJect formulations require high-purity excipients and specialty polymers with only a handful of GMP-compliant suppliers, concentrating supply and raising supplier leverage. Rigorous specifications and regulatory validation typically add 3–12 months of testing and qualification, inflating switching costs and inventory needs. During raw-material shortages or FDA inspections suppliers can tighten terms, raise prices, or delay shipments, materially impacting COGS and time-to-market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI sourcing and batch variability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAPI sourcing mixes commodity and niche inputs; in 2024 the industry remained concentrated, with industry estimates placing roughly 60% of small-molecule API capacity in China\/India, raising supplier leverage for niche APIs where few producers exist. GMP compliance and batch consistency are critical for ready-to-use stability; deviations often force reformulation or revalidation, delaying releases and raising COGS. Supplier performance directly affects release schedules and unit economics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh supplier concentration ≈60% China\/India (2024)\u003c\/li\u003e\n\u003cli\u003eFew producers for niche APIs = higher bargaining power\u003c\/li\u003e\n\u003cli\u003eGMP\/batch deviations → reformulation\/revalidation risk\u003c\/li\u003e\n\u003cli\u003eDelays raise COGS and push out release dates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTemperature-controlled distribution tightens the supplier ecosystem; qualified logistics and packaging providers are scarce and not easily interchangeable. The global cold-chain market topped $200 billion in 2024, concentrating bargaining power among certified carriers. Disruptions raise spoilage and write-off risk and carriers can pass through higher fees during capacity crunches.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScarcity of certified partners — concentration risk\u003c\/li\u003e\n\u003cli\u003eSpoilage from cold-chain failures reported at 10–20% in some pharma\/food segments\u003c\/li\u003e\n\u003cli\u003eCapacity crunches lead to carrier surcharges and volatile logistics costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: \u003cstrong\u003e\u0026gt;100\u003c\/strong\u003e shortages, \u003cstrong\u003e~60%\u003c\/strong\u003e API in China\/India\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier concentration gives CMOs, device makers and specialty-excipient\/API suppliers strong leverage over Xeris; in 2024 FDA listed \u0026gt;100 active drug shortages, ~60% of small-molecule API capacity was in China\/India, and the global cold-chain market topped $200B, with spoilage rates of 10–20% in some segments. Qualification\/validation timelines (3–24 months) and high switching costs sustain supplier bargaining power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA active shortages\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI capacity in China\/India\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain market\u003c\/td\u003e\n\u003ctd\u003e$200B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpoilage rates\u003c\/td\u003e\n\u003ctd\u003e10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualification lead-time\u003c\/td\u003e\n\u003ctd\u003e3–24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUncovers key drivers of competition, supplier and buyer power, substitute threats and entry barriers tailored exclusively for Xeris, with data-driven strategic commentary on disruptive forces and market dynamics to inform investor materials, business plans, and editable internal reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, one-sheet Xeris Porter's Five Forces summary with customizable pressure sliders and an interactive radar chart—perfect for quick strategic decisions, seamless slide\/report integration, and easy adaptation to evolving market conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFormulary gatekeepers (payers\/PBMs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayers and PBMs control formulary placement, tiers and prior authorizations, exerting heavy price pressure; the top three PBMs covered about 80% of US prescriptions in 2024. Therapeutic alternatives enable step edits or rebate-driven switches, with manufacturer rebates often reaching 40–50% on formulary-favored drugs. Payers demand real-world outcomes and demonstrable convenience to justify premiums, and sophisticated contracting by large buyers (Medicare Part D ~48M enrollees in 2024) favors their leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProvider systems and GPOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntegrated delivery networks and GPOs aggregate demand—95% of US hospitals belong to a GPO (Healthcare Supply Chain Association 2024), giving collective purchasing power in the hundreds of billions of dollars; they negotiate acquisition, handling and wastage terms, prioritize budget-impact models over convenience, and often exchange volume commitments for price concessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy and wholesaler channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDistribution intermediaries, led by McKesson, AmerisourceBergen and Cardinal Health which together controlled roughly 85% of US pharmaceutical distribution in 2024, dictate stocking and product availability to pharmacies. Fee-for-service structures and chargebacks materially reduce manufacturers’ net realized prices, while strict service levels and reduced days-of-inventory demands shift working capital pressure upstream. Ongoing consolidation of chains and wholesalers amplifies buyer leverage, compressing margins and negotiating terms. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient and caregiver preferences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUsability in emergencies is decisive for hypoglycemia rescue: as of 2024 both Eli Lilly's nasal Baqsimi and Xeris's injectable Gvoke are commercially available, and ease of use drives caregiver preference and adherence. Out-of-pocket costs can deter uptake despite convenience; manufacturer patient assistance programs partially offset costs but reduce net pricing to payers. Competing formats shape demand elasticity between nasal and injectable options.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUsability: decisive in emergencies\u003c\/li\u003e\n\u003cli\u003eMarket: Baqsimi and Gvoke available in 2024\u003c\/li\u003e\n\u003cli\u003eCosts: OOP deters adoption\u003c\/li\u003e\n\u003cli\u003eAssistance: lowers patient cost, hits net price\u003c\/li\u003e\n\u003cli\u003eFormat competition: affects elasticity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEndocrinologists and rare-disease specialists steer uptake of targeted Xeris brands; diabetes affects 37.3 million Americans (CDC 2022) and rare diseases impact an estimated 25–30 million (NIH), concentrating prescribing power. Strong evidence, guideline inclusion and sample experience drive adoption; switching costs exist but fall if benefits are clear, and KOL endorsements can offset payer friction.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical concentration: specialists drive demand\u003c\/li\u003e\n\u003cli\u003eEvidence\/guidelines: critical for uptake\u003c\/li\u003e\n\u003cli\u003eSamples lower initial friction\u003c\/li\u003e\n\u003cli\u003eKOLs mitigate payer resistance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyer power: PBMs ≈80%, Part D 48M, rebates \u003cstrong\u003e40–50%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers\/PBMs (top 3 ≈80% US scripts in 2024) and Medicare Part D (~48M enrollees) exert strong price\/formulary leverage; rebates often 40–50%. GPOs (95% hospitals) and integrated buyers consolidate purchasing; Big 3 distributors control ~85% of pharma distribution, compressing manufacturer margins. Usability, OOP costs and specialist\/KOL influence moderate demand elasticity and adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003eTop 3 share\u003c\/td\u003e\n\u003ctd\u003e≈80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D\u003c\/td\u003e\n\u003ctd\u003eEnrollees\u003c\/td\u003e\n\u003ctd\u003e≈48M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\u003c\/td\u003e\n\u003ctd\u003eHospital membership\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eBig 3 share\u003c\/td\u003e\n\u003ctd\u003e≈85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebates\u003c\/td\u003e\n\u003ctd\u003eTypical range\u003c\/td\u003e\n\u003ctd\u003e40–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eXeris Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis Porter’s Five Forces analysis of Xeris provides a concise, actionable assessment of competitive dynamics across suppliers, buyers, entrants, substitutes, and rivalry. This preview is the exact, fully formatted document you’ll receive instantly after purchase—no placeholders, no mockups. Ready for immediate download and use to inform strategy or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55676039790969,"sku":"xerispharma-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/xerispharma-five-forces-analysis.png?v=1755813970","url":"https:\/\/portersfiveforce.com\/products\/xerispharma-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}